Condition: Primary Myelofibrosis (PMF) · Post Polycythemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF) · Sponsor: The University of Hong Kong
In this open-label single arm phase 2 study, approximately 20 patients with MF demonstrating suboptimal response to ruxolitinib monotherapy will be enrolled. Patients will continue to receive ruxolitinib at a stable dose and ropeginterferon alfa 2b will be added to the regimen.
This description comes directly from the study's public registry record.
Hainder Gill, MD · 852 22555859 · gillhsh@hku.hk
Always discuss trial participation with your own doctor first.
| Department of Medicine, Queen Mary Hospital | Hong Kong, Hong Kong | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06770842